CureVac enters clinical phase with mRNA vaccine
First data expected on intramuscular application of the newly developed vaccine
25-Oct-2018 -
CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the initiation of its Phase I dose-escalation clinical trial with the novel mRNA-based rabies vaccine, CV7202. This is the first-in-human clinical trial of CureVac’s naturally ...
clinical trials
CureVac
drug candidates
+6